Dr. Sobel earned his A.B from Cornell and M.D. magna cum lade from Harvard. He interned and was a resident at Brigham & Women's Hospital and a fellow at NHLBI. He was the Director of Cardiology at Washington University prior to becoming the Director of the Cardiovascular Research Institute and chair of the Department of Medicine here at UVM. He has received numerous awards, published more than 800 manuscripts and edited major research journals that currently include Coronary Artery Disease.

Research Interests

Dr. Sobel’s research has been supported by the NIH, the ADA, and the AHA as a Program Director, Specialized Center of Research (SCOR) in Ischemic Heart Disease; Program Director, Collaborative Clinical Trial of Therapy to Protect Ischemic Myocardium; Program Director, Principles in Cardiovascular Research, National Institutes of Health Training Grant; Co-Investigator, Hemostasis & Thrombosis Program for Trainees, National Institutes of Health; Co-Investigator, Postdoctoral Cardiovascular Research Training Program, National Institutes of Health; Principal Investigator, BARI 2D Fibrinolysis and Coagulation Core R01HL63804, National Institutes of Health, 2000-2007; and Principal Investigator, Inflammation, Procoagulation, and Plaque Vulnerability R01HL71305, National Institutes of Health, 2000-2007. He served major cardiovascular and medical scientific journals including: Circulation, editor; Journal of Clinical Investigation, associate editor; American Journal of Physiology, associate editor; Coronary Artery Disease, presently editor; Current Opinion in Cardiology, editor; Fibrinolysis, associate editor; and Circulation Research, Annals of Internal Medicine, American Journal of Cardiology, American Journal of Medicine, Diabetes Care, editorial board member; published more than 800 manuscripts focusing on quantification of infarct size with the use of biomarkers and positron emission tomography; favorable modification of infarct size with clot selective fibrinolytic agents; elucidation of molecular mechanisms underlying evolution of vulnerable atherosclerotic plaques associated with insulin resistance and type 2 diabetes mellitus; and delineation of mechanisms potentiating heart failure in diabetes.

CMB Lab Members